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Twenty companies in the San
Francisco Bay Area each hauled in
US$20 million or more of venture
capital in the first quarter of 1999.
Nineteen of those companies aim to
make money from the internet. The
lone biotech, almost lost in the sea of
dot coms, was IntraBiotics
Pharmaceuticals, Inc. (Mountain
View, California). 
Former venture capitalist
Kenneth Kelley started IntraBiotics
in 1994 with the idea of using a big
pharma strategy — technology piracy
— against the mounting problem of
antibiotic resistance. “I realized,”
says Kelley, “that I could form a
company, and skip the three or four
years of pre-clinical discovery time.”
Success, complacency and panic
Penicillin, the first antibiotic, was
discovered by Alexander Fleming in
1928, and first used to treat humans
by Howard Florey in 1941. It was a
miraculous development for soldiers
injured in World War II. Within a few
years, however, physicians detected
penicillin-resistant bacteria.
Methicillin was used as a replacement,
but by 1992 ~40% of hospital strains of
the common bacterium Staphylococcus
aureus were the methicillin-resistant,
or MRSA, form.
The last line of defense was the
glycopeptide vancomycin. In 1987,
vancomycin-resistant Enterococcus
faecalis (VREF) appeared in England
and France, quickly spreading to the
United States. VREF threatens only
those with compromised immune
systems, but in 1997 partial resistance
to vancomycin was detected in patient
isolates of the more virulent S. aureus
both in Japan and the United States.
Fully vancomycin-resistant S. aureus
(VRSA) is something that Richard
Locksley, an infectious diseases
expert at the University of California,
San Francisco, and member of the
IntraBiotics scientific advisory board,
calls “a particularly terrifying prospect.”
Big pharma was caught napping.
“There was a big lull [in antibiotics
research] in the 70s and 80s, following
on the heels of some really superb
drugs like the third-generation
cephalosporins, and some high
ranking comments that infectious
diseases were dead,” says Locksley.
“The rise of HIV put an end to that.”
Search for inspiration
In 1993 Kelley went searching for his
founding technology. “The
antibiotics crisis had by then moved
from the technical literature to the
lay press,” says Kelley. So when
Kelley toured several laboratories at
the University of California, Los
Angeles, naturally Robert Lehrer’s
was amongst them. Kelley knew of
Lehrer’s work on defensins —
peptides made in neutrophils that
help destroy ingested bacteria. 
A small company takes the big
pharma approach — judicious
poaching of others’ technology.
But Lehrer wanted to talk about
protegrins. “[Kelley’s] timing was
impeccable,” says Lehrer. “He came
to talk to me about defensins, but I
said, ‘We have something that is
actually better’.”
The protegrin story started with
Russian researcher Vladimir
Kokryakov, who Lehrer met when he
was visiting his son in St Petersburg.
Kokryakov moved his cash-starved
research to UCLA, and with Lehrer
found several antimicrobial peptides
in pigs that, compared to defensins,
were half the size, more potent, and
resistant to salt inhibition.
IntraBiotics is starting a phase III
trial for oral mucositis with a
modified, 17-amino-acid version of
protegrin-1 (Figure 1). Chemotherapy
patients are given a mouthwash to kill
the wide range of bacteria that invade
tissues damaged by anticancer drugs.
Most antibiotics fail to kill all the
different types of colonizing bugs, but
protegrin is active against both gram-
positive and gram-negative bacteria. 
Protegrins as a test case
Protegrins are representative of a
newly discovered but ancient class of
antibiotics — the antimicrobial
peptides. Whether derived from
silkmoths, crabs or cows, they work
by either forming pores or otherwise
disrupting membrane structure. Their
selectivity for bacteria arises largely
from their cationic charge: bacterial
cell membranes have greater negative
charge, and a higher electropotential
gradient. The absence of cholesterol
and presence of lipopolysaccharide
may also be important. 
Resistance to protegrins has not
been seen in vitro, perhaps because of
this mechanism of action. “To
fundamentally alter the characteristics
of the cell membrane requires a lot of
changes at once,” says John Fiddes,
IntraBiotics’ vice president for
research and development.
IntraBiotics is trying an aerosol of
protegrin-1 for lung infections, but
Fiddes says “there’s no really good
expectation for systemic protegrin
use” because the cationic peptides
are so sticky and do not penetrate
tissues. These physical characteristics
may explain why other companies
interested in antimicrobial peptides
are also trying topical indications. 
An alternative explanation comes
from Robert Hancock (University of
British Columbia, and an adviser at
Micrologix Biotech Inc.,Vancouver,
Canada; see Table 1). He says that
trials for topical indications are simply
cheaper and easier. As for the problem
of stickiness, he says, “there’s always
the possibility of judicious
formulation to get around that. A
liposomal formulation might work.”
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The first antimicrobial peptide
trials were run by Magainin
Pharmaceuticals Inc. (Plymouth
Meeting, Pennsylvania) using the
magainin peptide from frog skin.
Initial trials against impetigo (a skin
infection usually seen in children)
showed no difference compared with
controls. (“If the kids scrubbed their
faces with soap and water they got
better,” says Kelley.) Then a second
phase III trial for infected foot ulcers
in diabetic patients was conducted
using a comparison with an existing
antibiotic. The FDA wanted a placebo
trial and refused to approve the drug. 
Kelley says his medical indication
and drug are quite different. But
Magainin’s rejection, and the
departure of another company into
selling health bars on the home-
shopping network (Table 1), has had
an impact. “With the two failures of
Magainin, the feeling is that no one
company will succeed, so it has to be
cooperative,” says Hancock. “I think
Micrologix is hoping that IntraBiotics
will succeed, and vice versa. One
success will be considered a flash in
the pan, but two successes might be
considered a movement.”
The next candidate
With protegrin safely in trials, Kelley
asked his dedicated team of literature
searchers to find an abandoned but
promising lead. The result was
ramoplanin, a cyclic peptide isolated
in 1984 from an Actinoplanes culture by
what is now termed Biosearch Italia,
S.p.A. (Gerenzano, Italy). After being
spun out from Hoechst Marion
Roussel, Biosearch did not have the
resources for clinical development.
Kelley pounced on ramoplanin as a
potent antibiotic with no sign of
resistance development in vitro and a
completed phase I trial. IntraBiotics is
now in two prophylaxis trials: phase
III for intestinal VREF (which leaks
into the body during chemotherapy),
and phase II for nasal MRSA (which
can lead to post-surgical infections).
Ramoplanin is not directly
comparable to new drugs for
systemic gram-positive infections
such as Synercid (recently approved)
and ZYVOX (linezolid; positive
phase III results). “Topicals [such as
ramoplanin] can’t do anything about
bacteremia, and that’s the major use
for antibiotics,” says Fred Tenover,
chief of the nosocomial pathogen
branch at the Centers for Disease
Control (Bethesda, Maryland). But
Kelley says that a prophylactic is
used far more often than a last-resort
treatment like Synercid, and so is
financially important. The danger
with frequent usage is, of course,
resistance. “Typically, you get
resistance development in anything
from 1 to 20 years,” says Tenover.
“There haven’t been very many that
have made it to 20 years, with the
exception of vancomycin.”
IntraBiotics hopes that new targets
and no in vitro resistance mean that
time is on their side. Locksley says the
new drugs are important, but to slow
the cycle of resistance “there is no easy
road — you need a lot of education.”
The solution is less antibiotics — in
everything from animal feed and
house-cleaning agents, to useless
prescriptions for viral infections. “It’s a
misunderstanding of the public to
think that the world is a sterile place,”
says Locksley. “They must realize that
normal flora is a good thing.” Like
everyone else, IntraBiotics will have to
fight the idea that more is better. 
William A. Wells
1095 Market Street #516, San Francisco,
CA 94103-1628, USA; wells@biotext.com.
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Table 1
Other companies developing antimicrobial peptides.
Company Technology and status of trials
Magainin Pharmaceuticals Inc. New drug application for magainin as treatment for infected 
foot ulcers in diabetic patients refused by FDA. 
Periodontix Inc. Histatins from human saliva in phase II for gingivitis and phase 
I/II for oral candidiasis.
Applied Microbiology, Inc. Stalled in early trials with nisin, now selling Lite Bites® nutrition
bars in partnership with the QVC television network. 
Micrologix Biotech Inc. In phase II for the prevention of central venous catheter-related 
bloodstream infection.
Biosource Technologies Preclinical, using plant viruses to produce material. Have option
on new peptide macrocycle from primates.
Similar structures but contrasting
mechanisms of action. The protegrin-1 analog
IB-367 (a) forms a tight anti-parallel β-sheet
that disrupts membranes, whereas ramoplanin
(b) inhibits an enzyme involved in cell wall
synthesis. Figure courtesy of IntraBiotics.
